Zhenfei Li

2.0k total citations
60 papers, 1.4k citations indexed

About

Zhenfei Li is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Zhenfei Li has authored 60 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 13 papers in Molecular Biology and 13 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Zhenfei Li's work include Prostate Cancer Treatment and Research (17 papers), Hormonal and reproductive studies (12 papers) and Thin-Film Transistor Technologies (10 papers). Zhenfei Li is often cited by papers focused on Prostate Cancer Treatment and Research (17 papers), Hormonal and reproductive studies (12 papers) and Thin-Film Transistor Technologies (10 papers). Zhenfei Li collaborates with scholars based in China, United States and Hong Kong. Zhenfei Li's co-authors include Nima Sharifi, Mohammad Alyamani, Richard J. Auchus, Sunil Upadhyay, Sheng Wang, Lin Li, Fen Nie, Jianneng Li, Jorge A. García and Jiayan Liu and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Zhenfei Li

57 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhenfei Li China 21 544 520 302 222 216 60 1.4k
Koji Asano Japan 20 605 1.1× 234 0.5× 118 0.4× 104 0.5× 98 0.5× 90 1.5k
Shih-Ming Huang Taiwan 19 608 1.1× 134 0.3× 188 0.6× 451 2.0× 166 0.8× 43 1.4k
Yuhang Zhao China 22 427 0.8× 101 0.2× 102 0.3× 61 0.3× 227 1.1× 79 1.4k
Ming Lu China 23 1.3k 2.3× 165 0.3× 118 0.4× 66 0.3× 117 0.5× 59 1.9k
Jiejun Wang China 24 862 1.6× 292 0.6× 32 0.1× 56 0.3× 422 2.0× 128 1.8k
Hao Tang China 25 1.8k 3.4× 127 0.2× 134 0.4× 89 0.4× 864 4.0× 100 2.8k
Masao Yokoyama Japan 23 546 1.0× 251 0.5× 128 0.4× 125 0.6× 76 0.4× 103 1.8k
Dongtak Jeong United States 24 2.0k 3.6× 87 0.2× 130 0.4× 165 0.7× 487 2.3× 55 2.7k
Hana Totary-Jain United States 20 786 1.4× 91 0.2× 97 0.3× 117 0.5× 401 1.9× 24 1.5k
Bin Ouyang United States 20 690 1.3× 135 0.3× 112 0.4× 97 0.4× 150 0.7× 42 1.4k

Countries citing papers authored by Zhenfei Li

Since Specialization
Citations

This map shows the geographic impact of Zhenfei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenfei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenfei Li more than expected).

Fields of papers citing papers by Zhenfei Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenfei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenfei Li. The network helps show where Zhenfei Li may publish in the future.

Co-authorship network of co-authors of Zhenfei Li

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenfei Li. A scholar is included among the top collaborators of Zhenfei Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenfei Li. Zhenfei Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Luyao, Y. N. Zhang, Jingjing Chen, et al.. (2025). Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy. Proceedings of the National Academy of Sciences. 122(26). e2422267122–e2422267122. 2 indexed citations
2.
Yan, Weiwei, Yang Liu, Jiahui Chen, et al.. (2024). PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression. Journal of Clinical Investigation. 134(18). 5 indexed citations
3.
Zhang, Chunyi, Pan Tian, Wei Yu, et al.. (2024). Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity. Signal Transduction and Targeted Therapy. 9(1). 258–258. 6 indexed citations
4.
Yang, Yuhao, Kai Jiang, Shenglei Huang, et al.. (2023). Potential‐free sodium‐induced degradation of silicon heterojunction solar cells. Progress in Photovoltaics Research and Applications. 31(9). 939–948. 21 indexed citations
5.
Huang, Shenglei, Yuhao Yang, Junjun Li, et al.. (2023). Dipoles and defects caused by CO2 plasma improve carrier transport of silicon solar cells. Progress in Photovoltaics Research and Applications. 32(5). 283–290. 5 indexed citations
6.
Zhuang, Qian, Shengsong Huang, & Zhenfei Li. (2023). Prospective role of 3βHSD1 in prostate cancer precision medicine. The Prostate. 83(7). 619–627. 7 indexed citations
7.
Huang, Shengsong, Weiwei Yan, Qian Zhuang, et al.. (2023). Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer. Journal of Clinical Investigation. 133(24). 22 indexed citations
8.
Tan, Qilong, Xiaobo Gao, Xuefeng Qiu, et al.. (2022). Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors. Oncogene. 41(42). 4754–4767. 5 indexed citations
9.
Yang, Tao, Ying Liu, Yuanyuan Gao, et al.. (2022). Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell Reports Medicine. 3(5). 100608–100608. 18 indexed citations
10.
Huang, Rui, Xiaomeng Zhou, Qiong Wu, et al.. (2022). Kennedy’s disease presented with mastication fatigue combined with positive titin antibody: a case report. BMC Neurology. 22(1). 425–425.
11.
Liu, Ying, Tao Yang, Chengdang Xu, et al.. (2022). The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients. Translational Andrology and Urology. 11(8). 1169–1176. 1 indexed citations
12.
Wang, Shi, Zhenfei Li, Xiaotong Li, et al.. (2022). Plasma ApoB/AI: An effective indicator for intracranial vascular positive remodeling. Journal of the Neurological Sciences. 436. 120226–120226. 3 indexed citations
13.
Yang, Tao, Si Zhang, Yuanyuan Gao, et al.. (2021). Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application. The Journal of Steroid Biochemistry and Molecular Biology. 210(202). 105859–105859. 7 indexed citations
14.
Huang, Shengsong, et al.. (2021). Androgens in prostate cancer: A tale that never ends. Cancer Letters. 516. 1–12. 29 indexed citations
15.
Han, Yufei, Qian Zhuang, Bo Sun, et al.. (2021). Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism. Nature Communications. 12(1). 449–449. 38 indexed citations
16.
Wei, Gang, Honglin Sun, Kai Dong, et al.. (2021). The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy. Cell Metabolism. 33(10). 2021–2039.e8. 71 indexed citations
17.
Gao, Xiaomei, Charles S. Dai, Shengsong Huang, et al.. (2018). Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression. Clinical Cancer Research. 25(4). 1291–1301. 41 indexed citations
18.
Wang, Liang, Lin Li, Dong Wang, et al.. (2018). Nordihydroguaiaretic acid can suppress progression of experimental autoimmune encephalomyelitis. IUBMB Life. 70(5). 432–436. 5 indexed citations
19.
Alyamani, Mohammad, Zhenfei Li, Michael Berk, et al.. (2017). Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities. Cell chemical biology. 24(7). 825–832.e6. 37 indexed citations
20.
Li, Zhenfei, Andrew C. Bishop, Mohammad Alyamani, et al.. (2015). Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 523(7560). 347–351. 205 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Koji Asano Breakdown of academic impact, for papers by Shih-Ming Huang Breakdown of academic impact, for papers by Yuhang Zhao Breakdown of academic impact, for papers by Ming Lu Breakdown of academic impact, for papers by Jiejun Wang Breakdown of academic impact, for papers by Hao Tang Breakdown of academic impact, for papers by Masao Yokoyama Breakdown of academic impact, for papers by Dongtak Jeong Breakdown of academic impact, for papers by Hana Totary-Jain Breakdown of academic impact, for papers by Bin Ouyang
Rankless by CCL
2026